13th April 2022 | Pharma Updates

Aleor received USFDA approval for Lidocaine 2.5% and Prilocaine 2.5% Cream

Aleor Dermaceuticals (Aleor) has achieved final FDA approval for its Abbreviated New Drug Application (ANDA) for Lidocaine and Prilocaine Cream USP, 2.5 percent /2.5 percent.

FDA asked a pharmaceutical company to halt production, and four have issued show-cause orders

FDA, Nagpur division, has ordered one pharmaceutical company to halt production after discovering anomalies during a special drive conducted between January and March of this year.

Lupin seeks talent in digital health, diagnostics, and data science

Lupin is trying to expand its footprint in India, and its recruiting is linked to the opening of new business divisions. The company is seeking talent in digital health and medtech, as well as consumer-facing diagnostics roles.

LIV001 being developed and commercialised by SGS Quay Pharma in collaboration with Liveome

SGS Quay Pharma has signed a contract with Liveome for the formulation development and clinical manufacture of a targeted release formulation for the treatment of inflammatory bowel disease.

Through a trial, Britain broadens access to Pfizer's COVID antiviral medication

Britain will add Pfizer’s (PFE.N) oral antiviral COVID-19 therapy to a trial to determine how best to use the drug in its highly vaccinated population, the health ministry announced on Tuesday.

Aeglea BioTherapeutics Submits a Biologics License Application to the FDA

Aeglea stated that it has submitted a Biologics License Application to the FDA for pegzilarginase for the treatment of Arginase 1 Deficiency. At the time of the BLA application, Aeglea requested FDA Priority Review.

Salvat presenting phase 3 results on an ocular steroid to authorities

After completing phase 3 trials and beginning the approval procedure in the United States and Europe, Salvat is preparing to introduce an ocular corticosteroid therapy for inflammation and pain in cataract surgery patients.